Raymond James analyst Danielle Brill downgraded Disc Medicine to Outperform from Strong Buy with a $40 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Disc Medicine reports FY23 EPS ($3.42) vs ($45.05) last year
- Disc Medicine price target raised to $104 from $76 at Stifel
- Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
- Disc Medicine price target raised to $80 from $70 at BMO Capital